CJC-1295 / Ipamorelin

WHAT IT IS

This is a blend name, not a single molecule. It refers to combining a GHRH-receptor agonist with ipamorelin, a growth hormone secretagogue that activates the ghrelin receptor with high selectivity and minimal effect on cortisol or prolactin compared with older secretagogues.

The name "CJC-1295" is used inconsistently across sellers. Products labeled this way most often actually contain Modified GRF(1-29), also called Mod GRF 1-29 or CJC-1295 without DAC, a short-acting GHRH fragment. Some products instead use the original CJC-1295 with DAC, a chemically modified version built to bind albumin in the blood and stay active for days rather than hours.

These are pharmacologically different products with different durations of action, and a buyer cannot assume which one is in a given vial from the name alone.

FDA status: Neither ingredient, and no combination product containing them, is FDA-approved.

WHAT RESEARCHERS ARE STUDYING IT FOR

Research on the individual ingredients, mostly in small human and animal studies, has examined:

• GHRH-analog effects on pulsatile growth hormone and downstream IGF-1 release
• Ipamorelin's selectivity for the ghrelin receptor relative to older secretagogues like GHRP-6
• Sleep-related growth hormone secretion patterns
• Body composition and lean mass outcomes associated with sustained growth hormone elevation
• Whether combining a GHRH-pathway compound with a ghrelin-pathway compound produces an additive growth hormone pulse in humans

PROPOSED BIOLOGICAL MECHANISMS

Growth hormone release from the pituitary is normally driven by two separate signals: GHRH and ghrelin. A GHRH analog and a ghrelin-receptor agonist activate these two pathways independently, and animal and small human studies suggest combining the two produces a larger acute growth hormone pulse than either alone.

Ipamorelin was specifically developed to be more selective for growth hormone release than earlier secretagogues, with less spillover into cortisol and prolactin signaling in the research that has evaluated it.

Whether the DAC or non-DAC version of the GHRH-analog ingredient is used changes the duration and pattern of that pulse considerably, which is one reason formulation details matter more here than the marketing name suggests.

AREAS OF RESEARCH INTEREST

• Whether sustained, elevated growth hormone pulsing has measurable long-term benefits or risks compared with the body's normal pulsatile pattern
• How combination secretagogue use compares with single-agent use in the limited human data available
• What long-term effects, if any, prolonged GHRH/ghrelin receptor co-stimulation has on the pituitary and downstream endocrine axes

WHAT THE EVIDENCE CURRENTLY SUGGESTS

Each ingredient has its own separate, relatively small human and animal research base examining growth hormone and IGF-1 responses over short study periods.

There is essentially no published clinical research specifically testing this two-ingredient combination as a marketed product, so claims of superior or additive effect rest on mechanistic reasoning rather than direct trial evidence.

Formulations vary by seller. Because the underlying GHRH-analog ingredient itself can be either CJC-1295 with DAC or the shorter-acting Mod GRF 1-29 sold under the same popular name, a reader should verify exactly what a specific product actually contains before drawing any conclusion about its expected duration of action.